We assume that pancreatic CSCs characterized CD133 expression may have a survival advantage under unfavorable hypoxic conditions, since EMT has been demonstrated to contribute to drug resistance in pancreatic cancer [32,35]. This evidence concerns the gene PROM1 and pancreatic neoplasm.